CurrentRheuma — Vasculitis & polymyalgia rheumatica

Real-world avacopan use in ANCA-associated vasculitis: glucocorticoid exposure and healthcare resource utilization from US claims data

2026-11-14T17:15:27.870Z

Cohort study · Rheumatology (Oxford), 2026.

Janus Kinase inhibitors in refractory Takayasu arteritis: a systematic review and proportion meta-analysis of efficacy and safety

2026-11-13T09:15:36.833Z

Meta-analysis · Rheumatology (Oxford), 2026.

The clinical potential of serum autotaxin levels at diagnosis as a biomarker for current activity and subsequent complications in patients with microscopic polyangiitis and granulomatosis with polyangiitis

2026-11-09T17:15:24.911Z

Cohort study · Clin Exp Rheumatol, 2026.

Glycolipid metabolic changes during remission induction in ANCA-associated vasculitis: a retrospective study of the lipid paradox

2026-11-09T17:15:24.911Z

Cohort study · Clin Exp Rheumatol, 2026.

Serum cytokine profiling identifies distinct immune phenotypes in eosinophilic granulomatosis with polyangiitis: interleukin-25- and interleukin-5-driven eosinophilic subtypes

2026-11-09T17:15:24.911Z

Cohort study · Clin Exp Rheumatol, 2025.

Biomarker trajectories and risk of relapse in giant cell arteritis: a multicenter study

2026-11-08T06:15:45.107Z

Cohort study · Semin Arthritis Rheum, 2026.

Assessing vasculitis in Takayasu arteritis by ultrasound: results of OMERACT patient-based reliability exercises

2026-11-05T13:24:18.717Z

Research article · RMD Open, 2026.

Behçet's disease and pregnancy: retrospective study and updated review of the literature

2026-11-05T13:24:18.717Z

Cohort study · Clin Exp Rheumatol, 2026.

Environmental determinants of large vessel vasculitis onset: a scoping review with complementary narrative synthesis of genetic susceptibility

2026-11-05T13:24:18.717Z

Research article · Rheumatology (Oxford), 2026.

Factors associated with tocilizumab primary failure in the treatment of giant cell arteritis

2026-11-05T13:24:18.717Z

Diagnostic or prognostic study · Joint Bone Spine, 2026.

International recommendations for the use of imaging in the diagnosis and assessment of polymyalgia rheumatica

2026-11-05T13:24:18.717Z

Guideline or statement · Ann Rheum Dis, 2026.

Large vessel giant cell arteritis in remission: Is imaging useful as predictor for relapses?

2026-11-05T13:24:18.717Z

Cohort study · Rheumatology (Oxford), 2026.

Left ventricular assessment using speckle-tracking echocardiography in Behçet's disease: a systematic review and meta-analysis

2026-11-05T13:24:18.717Z

Meta-analysis · Clin Exp Rheumatol, 2026.

Rituximab vs Azathioprine for Eosinophilic Granulomatosis With Polyangiitis Maintenance Therapy: A Randomized Clinical Trial

2026-11-05T13:24:18.717Z

Randomized controlled trial · JAMA, 2026.

Invisible neuropsychiatric burden in Behçet's disease without central nervous system involvement: a phenotype-based comparison

2026-11-05T13:10:58.883Z

Cross-sectional study · Clin Exp Rheumatol, 2026.

A Canadian vasculitis patient-driven survey to highlight which prednisone-related side effects matter the most

2026-11-04T23:43:54.165Z

Cross-sectional study · Clin Exp Rheumatol, 2023. Patients reporting ≥1 glucocorticoids (GC)-related SE All

Clinical phenotype and complications of large vessel giant cell arteritis: A systematic review and meta-analysis

2026-11-04T23:42:37.367Z

Meta-analysis · Joint Bone Spine, 2023. LV-GCA vs C-GCA clinical features — LV-GCA vs C-GCA: mean age difference -4.53 years; age at diagnosis

Epidemiology and predictors of relapse in giant cell arteritis: A systematic review and meta-analysis

2026-11-04T23:42:37.367Z

Meta-analysis · Joint Bone Spine, 2022. CRR of first relapse: 1-year CRR 32% (95% CI 22-43%)

Risk of acute myocardial infarction, stroke, and venous thromboembolism among patients with anti-neutrophil cytoplasmic antibody-associated vasculitis in South Korea: A nationwide population-based study

2026-11-04T23:42:37.367Z

Cohort study · Joint Bone Spine, 2022. Overall cerebro-cardiovascular comorbidities (stroke, acute MI, VTE, PE) — Anti-neutrophil cytoplasmic antibody-associated vasculitis vs Controls: times higher overall risk 2.3; vs the general population; significantly higher

Traditional and disease-related cardiovascular risk factors in ANCA-associated vasculitis: A prospective, two-centre cohort study

2026-11-04T23:42:37.367Z

Cohort study · Joint Bone Spine, 2023. CV events, median follow-up 2.90 years: Patients with a CV event (14 non-fatal, 2 fatal) 16 (11%)

Early infectious risk in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis according to remission-induction therapy

2026-11-04T23:40:51.898Z

Cohort study · Scand J Rheumatol, 2022. Survival without severe infection, 6 months — RTX vs CYC; p = 0.69

The impact of a structured one–day seminar on disease–specific knowledge, lifestyle habits and disease impairment in ANCA–associated vasculitis. Results of a randomized, controlled study

2026-11-04T23:40:51.898Z

Randomized controlled trial · Scand J Rheumatol, 2021. Disease-specific knowledge score — Intervention vs Waiting list control: mean ± sd score difference 2.2 ± 1.0 (95% CI 0.1-4.3); p = 0.04

IgA Vasculitis Following COVID-19 Vaccination: A French Multicenter Case Series Including 12 Patients

2026-11-04T23:37:51.551Z

Cohort study · J Rheumatol, 2022. Presentation of IgAV after COVID-19 vaccination: Age, median (IQR 30.75-60.5) years 52.5

Immunosuppressive Therapies in Ear, Nose, and Throat Involvement in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: Results From a Multicenter Retrospective Cohort Study

2026-11-04T23:37:51.551Z

Cohort study · J Rheumatol, 2022. ENT activity at last visit — CYC vs RTX: aOR 0.59 (95% CI 0.33-1.06); P = 0.08; no statistically significant difference

Incidence and Prevalence of Polymyalgia Rheumatica and Giant Cell Arteritis in a Healthcare Management Organization in Buenos Aires, Argentina

2026-11-04T23:37:51.551Z

Cohort study · J Rheumatol, 2022. PMR incident cases 825

The Reclassification of Patients With Previously Diagnosed Eosinophilic Granulomatosis With Polyangiitis Based on the 2022 ACR/EULAR Criteria for Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

2026-11-04T23:37:51.551Z

Cohort study · J Rheumatol, 2022. Reclassified as EGPA by 2022 ACR/EULAR criteria (concordance rate): Reclassified as EGPA 44 (86.3%)

Tocilizumab in Behçet Disease: A Multicenter Study of 30 Patients

2026-11-04T23:37:51.551Z

Cohort study · J Rheumatol, 2023. Overall response (complete or partial), 6 months: TCZ 25 (83%); Complete responders 18 (60%); Partial responders 7 (23%)

Traditional and Disease-Specific Risk Factors for Cardiovascular Events in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Multinational Retrospective Study

2026-11-04T23:37:51.551Z

Cohort study · J Rheumatol, 2023. Cardiovascular events (mostly MIs), median follow-up 62.0 months (IQR 22.6-100.0): AAV 245 (10.7%)

Validation of the Antineutrophil Cytoplasmic Antibody Renal Risk Score and Modification of the Score in a Chinese Cohort With a Majority of Myeloperoxidase-Positive Patients

2026-11-04T23:37:51.551Z

Cohort study · J Rheumatol, 2023. Discrimination for ESKD (C-index): Nomogram: C-index, development set 0.838 (range 0.785-0.891); C-index, validation set 0.794 (range 0.774-0.814); C-index, all-data set 0.822 (range 0.775-0.869) · Renal risk score: C-index, development set 0.801 (range 0.748-0.854); C-index, validation set 0.746 (range 0.654-0.838); C-index, all-data set 0.783 (range 0.736-0.830)

Anti-TNF vs tocilizumab in refractory uveitic cystoid macular edema due to Behcet's disease. Multicenter study of 49 patients

2026-11-04T23:02:07.938Z

Cohort study · Semin Arthritis Rheum, 2022. Macular thickness: Macular thickness progressively decreased in the 3 groups, with no signs of CME after 1 year of treatment

Effectiveness of a two-year tapered course of tocilizumab in patients with giant cell arteritis: A single-centre prospective study

2026-11-04T23:02:07.938Z

Cohort study · Semin Arthritis Rheum, 2023. Relapse in the 6 months after tocilizumab discontinuation, 6 months after discontinuation: Tocilizumab 6 (26%)

Efficacy and safety of leflunomide in the management of large vessel vasculitis: A systematic review and metaanalysis of cohort studies

2026-11-04T23:02:07.938Z

Meta-analysis · Semin Arthritis Rheum, 2023. At least partial remission (pooled proportion): TAK 75% (95% CI 0.64-0.84) · GCA 60% (CI 0.17-0.95)

Efficacy and tolerance of methotrexate in a real-life monocentric cohort of patients with giant cell arteritis

2026-11-04T23:02:07.938Z

Cohort study · Semin Arthritis Rheum, 2023. Relapsed during MTX treatment 25 (51%)

Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica: A scoping review by the OMERACT irAE working group

2026-11-04T23:02:07.938Z

Research article · Semin Arthritis Rheum, 2022. Publications identified 69

Impact of previous glucocorticoid therapy on diagnostic accuracy of [18F] FDG PET-CT in giant cell arteritis

2026-11-04T23:02:07.938Z

Cohort study · Semin Arthritis Rheum, 2023. PET-CT positivity (uptake grade 3 or 2): MP boluses 37%; MP 125 mg 80%; MP 250 or 500 mg 33%; MP 1 g 0% · New-onset GCA, high-dose oral GC: treated <2 weeks 54.5%; treated 2 to 4 weeks 38.5%; treated 4 to 6 weeks 25% · Relapsing/refractory GCA or prior PMR 54%

Increased arterial stiffness and accelerated atherosclerosis in Takayasu arteritis

2026-11-04T23:02:07.938Z

Cross-sectional study · Semin Arthritis Rheum, 2023. Carotid IMT, plaques and SWE (arterial stiffness): Mean IMT in right and left carotid arteries significantly higher only in TAK vs SLE and HCs

Is there a role for Pneumocystis jiroveci pneumonia prophylaxis in giant cell arteritis or polymyalgia rheumatica?

2026-11-04T23:02:07.938Z

Meta-analysis · Semin Arthritis Rheum, 2022. Incidence of PJP, first 6 months of therapy: GCA 0 (0 per 1,000 person-years); follow-up 547 patient-years · PMR 1 (0.07 cases per 1,000 patient-years); follow-up 7,446 patient-years

Outcomes in ANCA-associated vasculitis patients with end-stage kidney disease on renal replacement therapy—A meta-analysis

2026-11-04T23:02:07.938Z

Meta-analysis · Semin Arthritis Rheum, 2023. Pooled mortality rate per 100 py: Pooled mortality rate per 100 py 10.90

Prognostic factors in giant cell arteritis associated aortitis with PET/CT and CT angiography at diagnosis

2026-11-04T23:02:07.938Z

Cohort study · Semin Arthritis Rheum, 2023. At least one relapse, during follow-up: Ao-CTA+/PET+ 45 (70%) · Ao-CTA-/PET+ 5 (29%)

Takayasu arteritis and large-vessel giant cell arteritis in Italian population. Comprehensive analysis from a single institutional cohort of 184 cases

2026-11-04T23:02:07.938Z

Cohort study · Semin Arthritis Rheum, 2023. Clinical characteristics at presentation, diagnosis: LV-GCA: higher prevalence of males p = 0.003

Long delay from symptom onset to first consultation contributes to permanent vision loss in patients with giant cell arteritis: a cohort study

2026-11-04T22:58:59.711Z

Cohort study · RMD Open, 2023. PVL: PVL 49 (17.4%)

Metabolic features and glucocorticoid-induced comorbidities in patients with giant cell arteritis and polymyalgia rheumatica in a Dutch and Danish cohort

2026-11-04T22:58:59.711Z

Cohort study · RMD Open, 2023. Metabolic features at baseline vs Lifelines, before treatment: Glycated haemoglobin tended to be higher in treatment-naïve GCA vs Lifelines

Prevalence and risk factors of osteonecrosis of the femoral head in patients with ANCA-associated vasculitis: a multicentre cohort study

2026-11-04T22:58:59.711Z

Cohort study · RMD Open, 2023. ONFH prevalence: Patients diagnosed with ONFH 33 (18%)

Score to assess the probability of relapse in granulomatosis with polyangiitis and microscopic polyangiitis

2026-11-04T22:58:59.711Z

Diagnostic or prognostic study · RMD Open, 2023. Variables at diagnosis associated with relapse risk: PR3 positivity, HR (95% CI 1.28 to 2.57); p<0.001 1.81

Stable incidence but increase in prevalence of ANCA-associated vasculitis in southern Sweden: a 23-year study

2026-11-04T22:58:59.711Z

Cohort study · RMD Open, 2023. Average annual incidence/million adults, 1997-2019: GPA 15.4 (95% CI 13.3 to 17.6) /million adults · MPA 12.8 (95% CI 10.8 to 14.8) /million adults · EGPA 1.8 (95% CI 1.1 to 2.6) /million adults

Distinct gene signatures of monocytes and B cells in patients with giant cell arteritis: a longitudinal transcriptome analysis

2026-11-04T22:57:04.788Z

Mechanistic study · Arthritis Res Ther, 2023. Gene signatures characteristic of GCA: Differentially expressed genes among all patients and HCs (repeated measures ANOVA) 739

Elevated serum immunoglobulin level predicts high risk of 1-year recurrence in patients with Takayasu arteritis

2026-11-04T22:57:04.788Z

Cohort study · Arthritis Res Ther, 2023. Disease activity: Elevated immunoglobulins 3.0; ITAS-A 9.0 · Normal 2.0; ITAS-A 7.0

Gut dysbiosis is associated with aortic aneurysm formation and progression in Takayasu arteritis

2026-11-04T22:57:04.788Z

Cohort study · Arthritis Res Ther, 2023. Gut microbiota composition: TAK showed altered gut microbiota with higher abundance of oral-derived bacteria (e.g. Streptococcus, Campylobacter) than HCs, regardless of disease activity

Integrative metabolomics of plasma and PBMCs identifies distinctive metabolic signatures in Behçet’s disease

2026-11-04T22:57:04.788Z

Case-control study · Arthritis Res Ther, 2023. Plasma metabolic dysfunction in BD in carbohydrate, hydroxy fatty acid and polyunsaturated fatty acid metabolisms

Interplay between chronic inflammation and clonal haematopoiesis of indeterminate potential in Behçet’s disease

2026-11-04T22:57:04.788Z

Cross-sectional study · Arthritis Res Ther, 2023. CHIP detected: BD 11.1% · Control 13.9%